Suchirayu HealthCare Solutions

Nov 23, 2021

With the transaction, HCG has increased its holding in Suchirayu from the existing 17.7 per cent to 78.6 per cent, the company said in a statement. PTI November 22, 2021 / 11:26 AM IST The medicine is the first oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of mild-to-moderate COVID-19 in adults. (Representative image) Cancer focused healthcare service provider HealthCare Global Enterprises Limited (HCG) on Monday said it has become a majority stakeholder in Suchirayu Healthcare Solutions with the acquisition of additional 60.9 per cent for an undisclosed sum. With the transaction, HCG has increased its holding in Suchirayu from the existing 17.7 per cent to 78.6 per cent, the company said in a statement. Suchirayu owns a multi-speciality hospital in Hubli with an operational capacity of 110 beds and a potential to scale up to 250 beds. HCG has operated and maintained the hospital since August 2017 and had the right to increase its stake up to 80 per cent, the statement said. "Having operated Suchirayu for the past four years with successful patient outcomes and desired financial results, acquiring a majority was a logical step in cementing our presence in the region. We are confident that we will be able to derive multiple synergies with this acquisition," HCG Executive Chairman BS Ajaikumar said. HCG continues on its path to optimise capital allocations around cancer care and strengthen its pre-eminent position in the country, he added. HCG continues on its path to optimise capital allocations around cancer care and strengthen its pre-eminent position in the country, he added.